Novavax, Inc. (NVAX): Interesting Series Of Developments Taking Place

Novavax, Inc. (NASDAQ:NVAX) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 326.65M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Novavax, Inc. (NASDAQ:NVAX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NVAX, the company currently has 105.98 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 355.71 million in total assets, balanced by 414.77 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Novavax, Inc. (NVAX) saw -13.64 million in free cash flow last quarter, representing a quarterly net change in cash of -1.71 million. Perhaps most importantly where cash movements are concerned, the company saw about -12.4 million in net operating cash flow.

Novavax, Inc. (NASDAQ:NVAX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 6.73 million in total revenues. That represents a quarterly year/year change in revenues of 1.68 in sequential terms, the NVAX saw sales decline by 0.18.

But what about the bottom line? After all, that’s what really matters in the end. Novavax, Inc. (NVAX) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 283.44 million, this means overall earnings per share of -0.16. Note, this compares with a consensus analyst forecast of -0.16 in earnings per share for its next fiscal quarterly report.

Is Novavax, Inc. (NASDAQ:NVAX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.53 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Novavax, Inc..

Previous ArticleNext Article

Related Post

Financially Devastating or Fantastic? – Worl... The shares of Worldpay, Inc. Class A have increased by more than 8.42% this year alone. The shares recently went up by 1.28% or $1.01 and now trades a...
Cisco Systems, Inc. (CSCO) Is Driving on Undecided... Cisco Systems, Inc. (NASDAQ:CSCO) fell by -1.13% in Monday’s trading session from $34.43 to $34.04 The stock price went upward in 6 of the last 10 day...
ADT Inc. (ADT) vs. Cimarex Energy Co. (XEC): Compa...   ADT Inc. (NYSE:ADT) shares are down more than -16.46% this year and recently decreased -3.45% or -$0.37 to settle at $10.35. Cimarex Energy ...
A Comparison of Top Movers: ContraVir Pharmaceutic... The shares of ContraVir Pharmaceuticals, Inc. have decreased by more than -62.00% this year alone. The shares recently went down by -7.41% or -$0.03 a...
Which of 2 stocks would appeal to long-term invest... The shares of Platform Specialty Products Corporation have increased by more than 12.80% this year alone. The shares recently went up by 5.57% or $0.5...